Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats

Journal of Psychiatry and Neuroscience

Volumn 37, Issue 6, 2012, Pages 407-415

  Boyda, Heidi N ^a   Procyshyn, Ric M ^a,b   Tse, Lurdes ^a   Hawkes, Erin ^a   Jin, Chen Helen ^a   Pang, Catherine C Y ^a   Honer, William G ^a,b   Barr, Alasdair M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Mental Health and Addictions Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868266392     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.110140     Document Type: Article

References (68)

1. Honer WG, Thornton AE, Sherwood M, et al. Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. CNS Drugs 2007;21:699-714.
2. Procyshyn RM, Honer WG, Wu TK, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 2010;71:566-73.
3. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012;38:167-77.
4. Kessing LV, Thomsen AF, Mogensen UB, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010;197:266-71.
5. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(Suppl 4):8-13.
6. Procyshyn RM, Wasan KM, Thornton AE, et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 2007;32:331-8.
7. Hasnain M, Fredrickson SK, Vieweg WV, et al. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep 2010;10:209-16.
8. Sengupta S, Parrilla-Escobar MA, Klink R, et al. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls? Schizophr Res 2008;102:329-36.
9. Park T, Usher K, Foster K. Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics. Int J Ment Health Nurs 2011;20:428-37.
10. von Hausswolff-Juhlin Y, Bjartveit M, Lindstrom E, et al. Schizophrenia and physical health problems. Acta Psychiatr Scand Suppl 2009;(438):15-21.
11. Hafidh S, Senkottaiyan N, Villarreal D, et al. Management of the metabolic syndrome. Am J Med Sci 2005;330:343-51.
12. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006;10:515-31.
13. Leclerc I, Woltersdorf WW, da Silva Xavier G, et al. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab 2004;286:E1023-31.
14. Morioka K, Nakatani K, Matsumoto K, et al. Metformin-induced suppression of glucose-6-phosphatase expression is independent of insulin signaling in rat hepatoma cells. Int J Mol Med 2005;15: 449-52.
15. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270:12953-6.
16. Irwin N, McKinney JM, Bailey CJ, et al. Acute and long-term effects of peroxisome proliferator-activated receptor-gamma activation on the function and insulin secretory responsiveness of clonal beta-cells. Horm Metab Res 2011;43:244-9.
17. Sturgess NC, Ashford ML, Cook DL, et al. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 1985;2: 474-5.
18. Park S, Hong SM, Lee JE, et al. Chlorpromazine exacerbates hepatic insulin sensitivity via attenuating insulin and leptin signaling pathway, while exercise partially reverses the adverse effects. Life Sci 2007;80:2428-35.
19. Tulipano G, Rizzetti C, Bianchi I, et al. Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology 2007;85:61-70.
20. Boyda HN, Tse L, Procyshyn RM, et al. Preclinical models of anti-psychotic drug-induced metabolic side effects. Trends Pharmacol Sci 2010;31:484-97.
21. Boyda HN, Tse L, Procyshyn RM, et al. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:945-54.
22. Chintoh AF, Mann SW, Lam L, et al. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res 2009;108:127-33.
23. Smith GC, Chaussade C, Vickers M, et al. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 2008;51:2309-17.
24. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007;32:289-97.
25. Cooper GD, Pickavance LC, Wilding JP, et al. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 2007; 21:405-13.
26. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002;63:425-33.
27. Smith RC, Lindenmayer JP, Davis JM, et al. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry 2009;70:1501-13.
28. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
29. Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry 2010;55:117-25.
30. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008;101:273-86.
31. Boyda HN, Procyshyn RM, Tse L, et al. Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology 2012;62:1391-400.
32. Geyer MA, Krebs-Thomson K, Braff DL, et al. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001;156:117-54.
33. Sieber FE, Zakriya KJ, Gottschalk A, et al. Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair [published erratum in Mayo Clin Proc 2010;85:400. Dosage error in article text]. Mayo Clin Proc 2010;85:18-26.
34. Hauton D. Does long-term metformin treatment increase cardiac lipoprotein lipase? Metabolism 2011;60:32-42.
35. Kiss E, Popovic ZV, Bedke J, et al. Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allo-graft damage. Am J Pathol 2010;176:2150-62.
36. Barr AM, Young CE, Sawada K, et al. Abnormalities of presynaptic protein CDCre1-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia. Eur J Neurosci 2004;20:303-7.
37. Weston-Green K, Huang XF, Deng C. Sensitivity of the female rat to olanzapine-induced weight gain - Far from the clinic? Schizophr Res 2010;116:299-300.
38. Fell MJ, Anjum N, Dickinson K, et al. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berl) 2007;194:221-31.
39. Kalinichev M, Rourke C, Daniels AJ, et al. Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology (Berl) 2005;182:220-31.
40. Minet-Ringuet J, Even PC, Lacroix M, et al. A model for antipsy-chotic-induced obesity in the male rat. Psychopharmacology (Berl) 2006;187:447-54.
41. Smith GC, Vickers MH, Shepherd PR. Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch Physiol Biochem 2011;117:241-9.
42. Cooper GD, Pickavance LC, Wilding JP, et al. A parametric analy-sis of olanzapine-induced weight gain in female rats. Psychophar-macology (Berl) 2005;181:80-9.
43. Wallingford NM, Sinnayah P, Bymaster FP, et al. Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology 2008;33:2922-33.
44. Chintoh AF, Mann SW, Lam L, et al. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 2008;28:494-9.
45. Martins PJ, Haas M, Obici S. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 2010;59:2418-25.
46. LeBrasseur NK, Kelly M, Tsao TS, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006;291:E175-81.
47. Boyle JG, Salt IP, McKay GA. Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target. Diabet Med 2010;27:1097-106.
48. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-9.
49. Stephenne X, Foretz M, Taleux N, et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 2011;54:3101-10.
50. Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002;277: 25226-32.
51. Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012;122:253-70.
52. Chau-Van C, Gamba M, Salvi R, et al. Metformin inhibits adenosine 5′-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology 2007;148:507-11.
53. Kim SF, Huang AS, Snowman AM, et al. From the cover: Antipsychotic drug-induced weight gain mediated by histamine H1 recep-tor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 2007;104:3456-9.
54. Sejima E, Yamauchi A, Nishioku T, et al. A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats. Cell Mol Neurobiol 2011;31:985-9.
55. Molloy AM, Ardill J, Tomkin GH. The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects. Diabetologia 1980;19:93-6.
56. Mulherin AJ, Oh AH, Kim H, et al. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the in-testinal L cell. Endocrinology 2011;152:4610-9.
57. Maida A, Lamont BJ, Cao X, et al. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia 2011;54:339-49.
58. Smith GC, Vickers MH, Cognard E, et al. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr Res 2009;115:30-40.
59. Ehret M, Goethe J, Lanosa M, et al. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry 2010;71: 1286-92.
60. Way JM, Harrington WW, Brown KK, et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001; 142:1269-77.
61. Lykkegaard K, Larsen PJ, Vrang N, et al. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res 2008;103:94-103.
62. Arulmozhi DK, Dwyer DS, Bodhankar SL. Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice. Life Sci 2006;79:1865-72.
63. Adeneye AA, Agbaje EO, Olagunju JA. Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats. Indian J Exp Biol 2011;49:332-8.
64. Praharaj SK, Jana AK, Goyal N, et al. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol 2011;71:377-82.
65. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011;342:d1309.
66. Baptista T, Rangel N, El Fakih Y, et al. Rosiglitazone in the assist-ance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry 2009;42:14-9.
67. Barr AM, Powell SB, Markou A, et al. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 2006;51:457-65.
68. Bain SC. Treatment of type 2 diabetes mellitus with orally administered agents: advances in combination therapy. Endocr Pract 2009;15:750-62.